Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
erythropoiesis-stimulating agent |
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B03XA12
|
| gptkbp:brand |
gptkb:Omontys
|
| gptkbp:CASNumber |
478297-67-4
|
| gptkbp:developedBy |
gptkb:Takeda
gptkb:Affymax |
| gptkbp:drugBank_ID |
DB08814
|
| gptkbp:hasMolecularFormula |
C222H350N64O131S10
|
| https://www.w3.org/2000/01/rdf-schema#label |
peginesatide
|
| gptkbp:legalStatus |
withdrawn
|
| gptkbp:mechanismOfAction |
erythropoietin receptor agonist
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
25027361 |
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
fever
nausea vomiting diarrhea edema dizziness fatigue headache hypertension back pain pruritus cough chest pain anaphylaxis rash hypotension arthralgia hyperkalemia upper respiratory tract infection muscle spasms |
| gptkbp:UNII |
Q1J8A4N2JZ
|
| gptkbp:usedFor |
anemia in chronic kidney disease
|
| gptkbp:withdrawn |
2013
serious hypersensitivity reactions |
| gptkbp:bfsParent |
gptkb:Omontys
|
| gptkbp:bfsLayer |
7
|